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ABSTRACT 
Introduction: Malignant neoplasm of the endometrium is the most common malignant neoplasm of the female reproductive 
system. Toll Like Receptors (TLR) play a significant role in innate and late-immunity against infections or damaged tissues. TLRs 
are also involved in the development of tumors in their natural microenvironment. TLRs play an important role in angiogenesis, 
necessary for survival and growth of the tumor. Hypoxia playing a critical role in angiogenesis,  carcinogenesis, tumor progression 
and distant metastasis is primarily mediated through hypoxia inducible factors (HIFs). Vascular endothelial growth factor family 
proteins (VEGF) are also strongly involved in tumor angiogenesis and their action is strongly associated with TLR receptors. 
Objectives: The aim of the study was to correlate the expression of selected TLRs and VEGFR’s as well as HIF1α with clini-
copathological data of endometrial cancer patients. 
Material and methods: 123 neoplastic endometrial samples  were included in the study.  51 samples of healthy endome-
trium served as control. The expression of TLR1, TLR2, TLR3, TLR4, VEGFR1 and VEGFR2, VEGF-A and HIF1α was examined 
after RNA isolation at the mRNA level by Real Time-PCR. 
Results: We have noted a significant correlation between the expression of selected TLR and VEGFR’s and clinical stage as 
well as pathological grading of endometrial cancer. 
Conclusions: Received correlations confirm a significant contribution of some TLR expression and the receptor for VEGF 
in the pathogenesis of epithelial endometrial cancer. 
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INTRODUCTION
Endometrial carcinoma is the most common malignant 
neoplasm of the female reproductive system worldwide. 
The increasing number of cases is related to the increasing 
number of women with endometrial cancer risk factors, both 
in Poland and in other developed countries.
Mechanisms regulating the carcinogenesis as well as 
the cell death process are not fully understood.
The solid tumor growth and its metastatic ability de-
pends mainly on the angiogenesis. Thus, the process of 
tumor vessels growing is a promising therapeutic target. 
In recent years, important progress in molecular targeted 
therapy, including antiangiogenetic therapy has been ob-
served. The issue limiting the efficacy of this kind of therapy 
is the drug resistance.  Therefore, further efforts to better 
understand and eliminate this resistance are required.  
In solid tumors the area of low oxygen tension, signifi-
cantly hypoxic when compared to the healthy tissue are ob-
served.  The solid tumor formation is accompanied by local 
hypoxia, which is often considered to be an independent 
prognostic factor in many malignancies [1]. Hypoxia-induci-
ble factor-1 (HIF-1) induced in the low oxygen tumor region 
is known to be an  important transcription factor, mediating 
the cellular activity in the low oxygen environment. Since 
the mid-eighties, research on their potential participation 
in the regulation of the cancer process is ongoing.
Toll-like receptors (TLRs) are type I transmembrane 
receptors that are involved in the recognition and trans-
mission of pathogens to the immune system. They also 
play an important role in tissue homeostasis. TLRs are 
a transmitter of information about damaged tissues, which 
may play a role in the phenomenon of cancer. TLRs are 
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a family of particles that recognize the structure of ligands 
derived from microorganisms or damaged host cells. Their 
name is related to their similarity to the protein coded by 
the Toll gene identified in Drosophila [2]. Binding of ligand 
and TLR plays a key role in innate and late immunity [3, 4]. 
The TLR family consists of at least 13 types [5]. Eleven 
of these (TLR1 to TLR11) have so far been identified in 
humans. They are located on the surface or in the cyto-
plasm of immune cells and recognize various molecules 
and molecular products (DAMP and PAMP). PAMPs are 
molecular products derived from pathogens. DAMPs are 
endogenous molecules released from damaged or dying 
cells. Both DAMP-dependent and PAMP-dependent im-
mune responses via TLR signals are known [6]. TLRs are 
also involved in the development of tumors in their natural 
microenvironment. The tumor microenvironment, includ-
ing cancer cells, normal cells subjected to the “stress-
ogenic” factor, stromal tissue and extracellular matrix, 
have recently been recognized as the main factor in the 
progression and metastasis of cancer [7]. Lowering the 
level of anti-cancer antibodies is the cause of decreased 
activity of infiltrating immune cells, resulting in cancer 
progression, angiogenesis and metastasis [8, 9]. Recent 
studies show that activated TLRs on tumor cells can sup-
press the anti-tumor effect and functions of infiltrating 
immune cells, thus altering the inflammatory response in 
a way that promotes tumor growth [10]. Epithelial cells 
of the female reproductive system can undergo neoplas-
tic transformation due to continuous TLR stimulation by 
PAMP. Four types of TLR (TLR2-5) were expressed in ovar-
ian cancer cell lines [11]. Activation of TLR4 promotes the 
survival of ovarian cancer cells by inducing the expression 
of antiapoptotic proteins [12]. It was also shown that 
TLR5 and TLR9 may contribute to the development of cer-
vical cancer [13, 14]. It seems that TLRs play an important 
role in angiogenesis necessary for survival and growth of 
the tumor. The main factor is vascular endothelial growth 
factor (VEGF) — involved in tumor angiogenesis and as-
sociated with TLR signals. Vascular endothelial growth 
factor (VEGF-A) is a key molecule involved in the process 
of angiogenesis. [15]. Over-expression of VEGF in tumor 
cells enhances tumor growth and metastasis in several ma-
lignancies, including endometrial cancer.  The structure of 
new vessels, induced by VEGF, is different from the one of 
normal vessels. Their different permeability leads to high 
interstitial pressure and further hypoxia, which stimulates 
additional VEGF production [16]. Solid tumors due to the 
characteristic hypoxia, which is a stress factor leading to 
the emergence and release of DAMP [17]. These ligands 
activate TLR signals and contribute to molecular abnor-
malities in the tumor microenvironment. However, under 
tumor conditions, the cells die through non-apoptotic 
pathways, mainly necrosis. DAMPs released from dam-
aged or dying cells are recognized by TLR on immune 
cells; subsequent disturbances of the signal recognized 
by TLR lead to the progression of cancer [18]. 
 The few data available in the literature refer to the po-
tential contribution of individual TRLs to tumorigenesis in 
endometrial cancer.
MATERIAL AND METHODS
A total of 123  women with uterine endometrial 
endometrioid cancer were enrolled to this study.  All 
patients included in the present study gave their writ-
ten informed consent. Post-operative tissues were sub-
jected to routine histopathological examination in which 
the histological type of the tumor, the clinical stage of the 
tumor according to FIGO, the degree of cellular differentia-
tion (grading), tumor size, lymph node status, involvement 
of surrounding tissues — ovaries, fallopian tubes, cervix, 
parametria – were assessed. The control group consisted of 
51 samples of healthy endometrium taken from surgically 
removed uteri for non-oncological reasons. Immediately 
after uterus resection, approx. 0.2 g cancer tissue sam-
ples, (from visible part of the tumor), removed from the 
uterus, were placed in RNAlater (Ambion, USA) for overnight 
incubation. Samples were subsequently stored at –80°C until 
RNA extraction. Clinico-pathological and demographic data 
of patients are presented in Table 1.
Methods
RNA extraction and cDNA synthesis
Total RNA was isolated from frozen samples of tissue 
using EXTRACTME Total RNA Kit (Blirt, Poland) according 
to manufacturer’s protocol. Quantity and quality of the 
isolated RNA were assessed spectrophotometrically. First 
strand cDNAs were obtained by reverse transcription of 
2 µg of total RNA using High Capacity cDNA Revers Tran-
scription Kit (Life Technology, USA) following the manu-
facturer’s protocol.
Quantitative real time PCR analysis
The relative expression levels of TLR1, TLR2, TLR3, 
TLR4 and VEGFR1 were analyzed by real time PCR using the 
TaqMan® Gene Expression Assays (Life Technology, USA) 
according to manufacturer’s instruction. Quantitative data 
were normalized to HPRT1 used as reference gene. The assays 
numbers for studied genes were as follows Hs00413978_m1 
— TLR1, Hs02621280_s1 — TLR2, Hs01551078_m1 — TLR3, 
Hs00152939_m1 — TLR4, Hs01052961_m1 — VEGFR1 and 
Hs02800695_m1 (reference gene). 
Each PCR reaction was performed in duplicate and in-
cluded 1 µl of cDNA, 3.5 µl water, 5 µl of 2x TaqMan® Universal 
PCR MasterMix (Life Technology, USA) and 0.5 µl of TaqMan® 
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Gene Expression Assays consisted of a pair unlabeled PCR 
primer and a TaqMan® probe with FAM™ dye label on the 5’ 
end and MGB nonfluorescent quencher on the 3’ end. The 
following PCR program was used: 95°C for 10 min, 40 cycles 
of 95°C for 15 s, 1 min annealing and extension at 60°C. PCR 
reactions were carried out using the Mastercycler ep realplex 
(Eppendorf, Germany). 
The equation 2-ΔCt was applied to calculate the expres-
sion of studied genes, where ΔCt = Ct of the target gene 
– Ct the reference gene (HPRT1). Results are expressed as 
a number of target gene mRNA copies per 1000 copies of 
HPRT1 mRNA.
The relative expression levels of VEGFR2, VEGF and 
HIF-1a were analyzed by real time PCR using SYBR Green 
reagent (Applied Biosystems, USA) according to Luczak et 
al., [1] and Amirchaghmaghi et al., (2015).
Statistical analysis
Statistical analysis was performed using PQStat ver-
sion 1.6.4 (PQStat Software, Poland). Differences of mRNA 
expression among groups were analyzed by non-parametric 
test (Mann-Whitney U test and Kruskal-Wallis test with post 
hoc multiple comparisons). Co-expression of genes was 
analyzed using the Spearman test. A value of p < 0.05 was 
considered statistically significance.
RESULTS
The expression of TLR1, TLR2, TLR3, TLR4, VEGFR1 VEG-
FR2, VEGF-A and HIF-1α at the mRNA level were correlated 
to clinical and pathological features.
1. Tumor size (pT)
a) TLR1 gene
The lowest values of the TLR1 gene were recorded in the 
T3-T4 endometrial cancer group. This difference was statistically 
significant when compared to the control (p < 0.002) (Fig. 1).
b) TLR2 gene
There were no statistically significant differences be-
tween the examined groups. 
c) TLR3 gene
There were highly significant differences between the 
examined groups. Both T1-T2 and T3-T4 groups revealed 
significantly lower expression of TLR3 (p < 0.0001) when 
compared to the control group (Fig. 1). 
d) TLR4 gene
There were no statistically significant differences be-
tween TLR4 gene expression in the examined groups.
e) VEGFR1 gene
The VEGFR1 gene expression in the control group was 
significantly lower than in the group of patients with small 
(T1-2) and large (T3-4) tumors (p < 0.003 and p < 0.0001, 
respectively). VEGFR1 expression for T1- T2 group did not 
differ from the T3-T4 group (Fig. 1). 
f ) VEGFR2 gene
The VEGFR2 gene expression in the control group was 
significantly higher than in the group of patients with small 
(T1-2) and large (T3-4) tumors (p < 0.0001 and p < 0.0001, 
respectively). VEGFR2 expression for T1- T2 group did not 
differ from the T3-T4 group (Fig. 1). 
g) VEGF-A gene
There were no statistically significant differences be-
tween the examined groups. 
h) HIF1α
The significantly lower expression of HIF1α was ob-
served only in a T1-T2 group when compared to the control 
(Fig. 1).
2. Lymph node status (pN)
a) TLR1 gene
The highest TLR1 expression was found in the control 
group. They differed significantly from the lowest values 
found in the group of patients with endometrial cancer 
without regional lymph node involvement (p < 0.05). There 
were no other significant differences in TLR1 expression 
between the examined groups (Fig. 2).
Table 1. Demographic and clinical-pathological characteristics of 
the study group
study group n (%) control group n (%)
group size n = 123 n = 51
age, the average age 68.50 ± 10.32
< 50 years 7 (5.69)
















no data 1 (0.83)
myometrium infiltration 
< 1/2 62 (50.04)
> 1/2 58 (47.15)
no data 3 (2.81)
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b) TLR2 gene
The expression of the TLR2 gene did not differ statisti-
cally between the control group and the group of patients 
with endometrial cancer regardless of nodal status.
c) TLR3 gene
TLR3 gene expression was significantly lower (at the 
same level of significance — p < 0.0001) in both endometrial 
cancer groups, i.e. regardless of the lymph node status, when 
compared to the control group (Fig. 2).
d) TLR4 gene
There were no statistically significant differences be-
tween TLR4 gene expression in the examined groups com-
pared to the control group.
e) VEGFR1 gene
The VEGFR1 gene expression was significantly higher 
(p < 0.0001) in the group of women with cancer regardless of 
the lymph node status, when compared to the control (Fig. 2).
f ) VEGFR2 gene
The VEGFR2 gene expression in the control group was 
significantly higher (p < 0.0001–0.0002) than in the cancer 
groups regardless of the lymph node status, when compared 
to the control (Fig. 2). 
g) VEGF-A gene
There were no statistically significant differences be-
tween the examined groups. 
h) HIF1α
Figure 1. Expression of the TLR, VEGFR and HIF-1alfa genes depending on the size of the tumor
Figure 2. Expression of the TLR, VEGFR and HIF-1alfa genes depending on the state of regional lymph nodes
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The significantly lower (p < 0.022) expression of HIF1α 
was observed only in a N0 group, when compared to the 
control (Fig. 2).
3. Tumor differentiation (G)
a) TLR1 gene
The lowest values of TLR1 gene expression were re-
corded in low-grade tumors (G3). This difference showed 
a high statistical significance (p < 0.0001) when related to 
G1, G2 and control group. TLR1 expression in groups G2 and 
G1 did not differ significantly from the control (Fig. 3).
b) TLR2 gene
The highest TLR2 gene expression values were observed 
in G1 tumors. Significant differences were found between well 
differentiated tumors (G1) in comparison to G2 and G3 tu-
mors. However, no statistically significant differences were 
found between the studied groups and the control (Fig. 3).
c) TLR3 gene
TLR3 gene expression is lower in all examined cancer 
groups regardless of the degree of tumor differentiation 
(G) when compared to the control. For all G groups, those 
relations were highly (p < 0.003, p < 0.0001) different (Fig. 3). 
d) TLR4 gene
Expression of the TLR4 gene did not differ statistically 
between the examined cancer groups when compared to 
the control.
e) VEGFR1 gene
VEGFR1 gene expression was significantly higher in all 
examined cancer groups, regardless of the tumor differ-
entiation (G) when compared to the control group. For all 
G degrees, these relations were characterized by high sta-
tistical significance (p < 0.003, p < 0.004) (Fig. 3). 
f ) VEGFR2 gene
VEGFR2 gene expression was significantly lower in 
all examined cancer groups, regardless of the tumor dif-
ferentiation (G) when compared to the control group. 
For all G degrees, these relations were characterized by 
high statistical significance (p < 0.0001, p < 0.0001 and 
p < 0.0008) (Fig. 3). 
g) VEGF-A gene
There were no statistically significant differences be-
tween the examined groups. 
h) HIF1α
The significantly lower expression of HIF1α was ob-
served only in G2 group when compared to the control 
(Fig. 3).
4. FIGO stage of endometrial cancer
a) TLR1 gene
There were no statistically significant differences in 
TLR1 gene expression related to FIGO stage between the 
examined groups and the control. 
b) TLR2 gene
There were no statistically significant differences in the 
expression of the TLR2 gene between the examined groups 
and the control.
c) TLR3 gene
In the examined groups of patients with endometrial 
cancer, the expression of the TLR3 gene was significantly 
lower, regardless of the FIGO stage, when compared to the 
control group (p < 0.0001) (Fig. 4).
d) TLR4 gene
There were no statistically significant differences in 
TLR4 gene expression between the examined groups and 
the control.
e) VEGFR1 gene
VEGFR1 gene expression was significantly higher 
(p < 0.0001) in the examined groups when compared to 
the control group, regardless of the FIGO stage (Fig. 4).
f ) VEGFR2 gene
Figure 3. Expression of the TLR, VEGFR and HIF-1alfa genes depending on the grade of malignancy of the tumor
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In the examined groups of patients with endometrial 
cancer, the expression of the VEGFR2 gene was significantly 
lower, regardless of the FIGO stage, when compared to the 
control (p < 0.0001) (Fig. 4).
g) VEGF-A gene
There were no statistically significant differences be-
tween the examined groups. 
h) HIF1α
The significantly lower (p < 0.0154) expression of HIF1α 
was observed only in FIGO I-II group when compared to the 
control (Fig. 4).
DISCUSSION
TLRs are a link that combines non-specific with spe-
cific immunity. Their role in the pathogenesis of malignant 
tumors is not fully understood. In the available literature, 
there are few data about the TRL receptor compound, with 
mechanisms related to cancer and the spread of tumors in 
the human body. It is known that the expression of certain 
types of TLRs is different in cancers of the ovary, cervix, large 
intestine, breast and others [10]. There are also some data 
on participation of the TLRs in physiological processes in the 
endometrium, as well as in endometrial hypertrophy and 
some post-partum pathologies [19]. Hypoxia playing a criti-
cal role in angiogenesis,  carcinogenesis, tumor progression 
and distant metastasis is primarily mediated through hyp-
oxia inducible factors (HIFs) [20]. In the available literature, 
however, there are few reports analyzing the potential im-
portance of TLRs in the pathogenesis of endometrial cancer 
and its relation to specific hypoxia markers.  
In our study, we correlated the expression of selected 
TLRs with angiogenic and hypoxia factors in relation to the 
clinico-pathological data.
Expression of TLR3 was significantly lower, regardless of 
the size of the tumor, represented in the pathomorphologi-
cal classification as a T feature, in relation to the control. In 
turn, TLR1 receptor expression only in advanced (T3-T4) tu-
mors, similarly as TLR3, was significantly reduced. These data 
are partly correlated with the report by Allhorn et al. [21], 
who evaluated the expression of TLR3 and TLR4 in various 
conditions of the endometrium and revealed, among oth-
ers, that TLR3 and TLR4 expression is significantly reduced 
in low-differentiated endometrial tumors. However, authors 
did not refer those results to the clinico-pathological data 
of the disease. In contrast to the above results, we did not 
demonstrate the important role of the TRL4 receptor in the 
pathogenesis of endometrial cancer. 
In turn, according to expectations and data from the 
literature [16, 22], the expression of VEGFR1 was significantly 
increased in cancer tissue, when compared to the control, 
irrespective of their size, grading, nodal status and FIGO 
stage. In contrast, the VEGFR2 expression was significantly 
decreased in the endometrial cancer samples in the tumor 
size independent manner. 
The relations between transcriptome and proteome 
is not a clear and direct issue. The protein and mRNA cel-
lular content might be influenced by many factors. One 
can suppose, the mRNA expression may be regulated by 
the negative feedback control mechanism. The protein to 
protein interactions may stabilize some proteins. This can be 
induced by protein’s physiological turnover disruption.
Protein halflive increases due to its stabilisation what 
is induced when components involved in normal protein’s 
turnover are disrupted or through protein to protein interac-
tions. This phenomenon may occur when downregulation of 
mRNA and simultaneous protein upregulation are observed. 
Akin to VEGFR1, VEGFR2 expression was related to the 
presence of malignancy regardless of tumor differentiation, 
nodal status and FIGO stage. This observation indirectly 
confirms the important role of VEGF receptors in the devel-
opment of endometrial cancer. 
In our study we were unable to demonstrate correlation 
between VEGF-A protein and clinico pathological data of 
examined tissues.
The presence of metastases in the lymph nodes did not 
influence on TLR3 expression. Significantly lower TLR3 ex-
pression was observed in cancerous tumors irrespective to 
the lymph node status. 
Tumor malignancy (G) is one of the most important, 
independent prognostic factors in endometrial cancer. 
We have demonstrated the highly significant correlation 
between cell differentiation and some TLRs, VEGFR1, VEG-
FR2 expression. Like in other clinic-pathologic factors, the 
expression of VEGFR1 and VEGFR2 were opposite when 
related to the tumor malignancy. 
Figure 4. Expression of the TLR, VEGFR and HIF-1alfa genes 
depending on the FIGO stage
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In undifferentiated tumors (G3), TLR3 expression was 
significantly lower than in the control group. It was also de-
creased in comparison to more differentiated tumors (G2 and 
G1), but this difference was not statistically significant. Similar 
results were obtained by Allhorn et al. [21]. Although the 
results given in the cited work were based on the analysis of 
only 16 cases of endometrial cancer, similarly to our results, 
the authors observed significantly lower TLR3 expression 
in all degrees of cellular differentiation. Different results on 
TLR4 expression in endometrial cancer tissue were presented 
by Allhorn et al. In our study, the expression of this receptor 
in tumor tissues did not differ from the control group, while 
Allhorn observed a relationship between TLR4 expression 
and tumor differentiation, like that found in TLR3 results.
Similarly, VEGF1 and VEFGR2 receptors expression were 
different in neoplastic tumors irrespective to the regional 
nodal involvement. This highly significant correlation, nega-
tive for VEGFR1 and positive for VEGRF2 seems to support 
the hypothesis of their direct involvement in cancerogenesis 
[23]. Similar results were obtained by [24] and [25]. 
Gene expression for VEGFR1 appears to be inversely 
related to TLR3 expression. Similar to the available data 
[18], in all malignant endometrial tumors, it was signifi-
cantly higher than in the control group. Analogous rela-
tions were observed by Giatromanolaki A et al. [26] who 
demonstrated that VEGFR expression is one of significant 
independent prognostic factors in epithelial endometrial 
tumors. In contrast, gene expression of VEGFR2 appeared 
to be directly related to TLR3 expression. The explanation 
of those differences needs further studies. 
Surprisingly, Hypoxia Inducible Factor-1α (HIF-1α) sup-
posed to play a key role in hypooxygenation of cancer tissue 
was not overexpressed in endometrial cancer tissue in more 
advanced, undifferentiated tumors. 
We have not found a highly significant correlation be-
tween lymph node involvement and the expression of HIF1α 
- the typical hypoxia marker. Those results stay in contrast to 
those published by Tawadros at al. [27] who observed a sig-
nificant association between HIF1α expression and lymph 
node involvement in endometrial cancer. The explanation 
of our observation needs further studies
The FIGO stage at the time of diagnosis is an important 
prognostic factor in endometrial tumors, apart from the 
degree of cancer differentiation. Studies on the relation-
ship between the expression of selected TLR’s and VEGFR 
receptors and the clinical stage of the disease allowed us to 
demonstrate statistically significant relations. FIGO III and IV 
stage tumors are associated with significantly lower TLR3 ex-
pression, high VEGFR1 expression and low VEGFR2 expres-
sion. Similar relationships were not stated for TLR1, TLR2 and 
TLR4. The HIF1α expression in relation to the FIGO stage did 
not present a statistically different relation. 
The relations observed in our study might confirm the 
hypothesis indicating a significant role of VEGF through 
selected TLRs in the pathogenesis of endometrioid endo-
metrial malignancies. Selected TLRs may influence the pro-
liferation of a tumor by inducing a response that causes the 
process of inhibiting tumor progression. In this process, the 
receptor for epidermal growth factor (VEGFR) appears to 
be an important factor. The possibility of pharmacological 
intervention in the immune response to the pathogenic 
molecular factors that trigger this response may be a promis-
ing alternative to the treatment of endometrial malignant 
tumors. However, this hypothesis requires further research.
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